Ipsen splurges $25M on its second rare disease drug pact of the year, with more on the way
Eight months after reeling in Clementia and their drug palovarotene in a $1.3 billion buyout deal, David Meek has another rare disease therapy to add to the pipeline at Ipsen.
The Paris-based biotech (EPA: $IPN) is fronting $25 million in cash to acquire worldwide rights to Blueprint’s BLU-782, an ALK2 inhibitor designed to fight an ultra-rare genetic condition called fibrodysplasia ossificans progressiva, or simply FOP. And there’s the full slate of $510 million more for milestones running through development, regulatory as well as commercial.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
